TNDM
USDTandem Diabetes Care Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$14.230
Kõrge
$15.355
Madal
$14.140
Maht
0.77M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
1.0B
Tööstusharu
Meditsiiniseadmed
Riik
United States
Kauplemisstatistika
Keskmine maht
2.13M
Börs
NGM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Tandem Diabetes Care Achieves ISO/IEC 27001:2022 Certification, Reinforcing Commitment to Global Data Security Standards
Certification affirms Tandem's company-wide commitment to cybersecurity, data protection, and operational integrity Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company,
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem...
Tandem Diabetes Care Announces Upcoming Conference Presentations
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: Stifel 2025
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tandem Diabetes Care, Inc. - TNDM
Pomerantz LLP is investigating claims on behalf of investors of Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ: TNDM). Such investors ...
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem...
Stifel Reinstates Hold on Tandem Diabetes Care, Announces $15 Price Target
Stifel analyst Jonathan Block reinstates Tandem Diabetes Care with a Hold and announces $15 price target.
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.